A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Seung Taek | - |
dc.contributor.author | Yu, Jong Han | - |
dc.contributor.author | Park, Heung Kyu | - |
dc.contributor.author | Moon, Byung In | - |
dc.contributor.author | Ko, Byung Kyun | - |
dc.contributor.author | Suh, Young Jin | - |
dc.date.available | 2020-02-28T17:46:39Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-03-13 | - |
dc.identifier.issn | 1477-7819 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12783 | - |
dc.description.abstract | Background: To investigate the clinicopathological characteristics and the survival outcomes of invasive lobular carcinoma (ILC) patients compared to invasive ductal carcinoma (IDC) patients according to their molecular subtype. Methods: We compared the clinicopathological characteristics, breast cancer-specific survival (BCSS) and overall survival (OS) between patients with IDC (n = 14,547) and ILC (n = 528). Results: The ILC presented with a larger tumor size, more advanced cancer stage, increased rate of hormonal receptor positivity, human epidermal growth factor 2 (HER2) negativity and mastectomy than the IDC. The ILC patients more frequently presented with the luminal A subtype, whereas the IDC patients more frequently presented with the luminal B, HER2-overexpression, or triple negative subtype. The BCSS and OS were not significantly different between the IDC and ILC for each molecular subtype. Conclusions: Similar to IDC patients, molecular subtype should be considered when determining the prognosis and treatment regimen for ILC patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.relation.isPartOf | WORLD JOURNAL OF SURGICAL ONCOLOGY | - |
dc.subject | TUMOR CHARACTERISTICS | - |
dc.subject | CANCER | - |
dc.subject | SURVIVAL | - |
dc.subject | THERAPY | - |
dc.subject | FEATURES | - |
dc.subject | SURGERY | - |
dc.subject | TRENDS | - |
dc.title | A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000335353600001 | - |
dc.identifier.doi | 10.1186/1477-7819-12-56 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF SURGICAL ONCOLOGY, v.12 | - |
dc.identifier.scopusid | 2-s2.0-84899155519 | - |
dc.citation.title | WORLD JOURNAL OF SURGICAL ONCOLOGY | - |
dc.citation.volume | 12 | - |
dc.contributor.affiliatedAuthor | Park, Heung Kyu | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Invasive lobular carcinoma | - |
dc.subject.keywordAuthor | Invasive ductal carcinoma | - |
dc.subject.keywordAuthor | Molecular subtype | - |
dc.subject.keywordAuthor | Breast cancer-specific survival | - |
dc.subject.keywordAuthor | Overall survival | - |
dc.subject.keywordPlus | TUMOR CHARACTERISTICS | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | FEATURES | - |
dc.subject.keywordPlus | SURGERY | - |
dc.subject.keywordPlus | TRENDS | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.